Novel IκκB kinase inhibitors for treatment of nuclear factor-κκB-related diseases

Author： Suzuki Jun-Ichi Ogawa Masahito Muto Susumu Itai Akiko Isobe Mitsuaki Hirata Yasunobu Nagai Ryozo

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.3, 2011-03, pp. : 395-405

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacoinformatic Approaches to Design Novel Inhibitors of Protein Kinase B Pathways in Cancer

Current Cancer Drug Targets, Vol. 18, Iss. 9, 2018-11 ,pp. : 830-846

Bentham Science Publishers

Access to resources Recommend Favorite

Nuclear factor-kappa B inhibitors; a patent review (2006 – 2010)

By Kwak Jae-Hwan Jung Jae-Kyung Lee Heesoon

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 12, 2011-12 ,pp. : 1897-1910

Informa Healthcare

Access to resources Recommend Favorite

NF-&kgr;B Inhibitors for the Treatment of Inflammatory Diseases and Cancer

Current Medicinal Chemistry, Vol. 14, Iss. 3, 2007-02 ,pp. : 367-376

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Dual Inhibitors of Nuclear Factor-Kappa B (NF-κ B) and Cyclooxygenase- 2 (COX-2): Synthesis, In Vitro Anticancer Activity and Stability Studies of Lantadene–Non Steroidal Anti-inflammatory Drug (NSAID) Conjugates

Current Topics in Medicinal Chemistry, Vol. 14, Iss. 8, 2014-04 ,pp. : 991-1004

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of erbB-1 kinase

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 12, 2002-12 ,pp. : 1903-1907

Informa Healthcare

Access to resources Recommend Favorite